Wang, Xuan
Luo, Zhiguo
Chen, Jing
Chen, Yu
Ji, Dongmei
Fan, Li
Chen, Ling
Zhao, Qian
Hu, Pei
Sun, Peng
Jia, Zhongwei
Guo, Jun
Si, Lu
Funding for this research was provided by:
Shanghai Kechow Pharma, Inc.
Article History
Received: 10 April 2022
Accepted: 18 November 2022
First Online: 4 January 2023
Declarations
:
: The study was done in accordance with Declaration of Helsinki and the Good Clinical Practice Guideline. The protocol and all amendments were approved by the institutional review board or independent ethics committee of each study site: Peking University Cancer Hospital (ethical approval number: 2017YW26); Fudan University Shanghai Cancer Center (ethical approval number: 1712179–4-1811A); Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (ethical approval number: 2019105); Fujian Medical University Cancer Hospital (ethical approval number: 2019–040-01). All patients provided written informed consent.
: Not applicable.
: L.S. has received speakers’ honoraria from MSD, Roche, Novartis, Shanghai Junshi Biosciences and Oriengene. J.G has served on advisory boards/consulted for MSD, Roche, Pfizer, Bayer, Novartis, Simcere, Shanghai Junshi Bioscience, and Oriengene. All other authors declared no potential competing interests with respect to the research, authorship, and/or publication of this article.